Published in Mayo Clin Proc on July 01, 2006
The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther (2010) 2.07
Update on gout: new therapeutic strategies and options. Nat Rev Rheumatol (2010) 2.02
Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing. Clin Pharmacol Ther (2012) 1.72
Patients and providers view gout differently: a qualitative study. Chronic Illn (2010) 1.60
Comparative effectiveness of urate lowering with febuxostat versus allopurinol in gout: analyses from large U.S. managed care cohort. Arthritis Res Ther (2015) 1.48
Medication adherence of patients with selected rheumatic conditions: a systematic review of the literature. Semin Arthritis Rheum (2008) 1.38
Adherence with urate-lowering therapies for the treatment of gout. Arthritis Res Ther (2009) 1.35
Patients' knowledge and beliefs concerning gout and its treatment: a population based study. BMC Musculoskelet Disord (2012) 1.15
Quality of life and quality of care for patients with gout. Curr Rheumatol Rep (2009) 1.12
Why is gout so poorly managed? Ann Rheum Dis (2007) 1.09
Induced and pre-existing anti-polyethylene glycol antibody in a trial of every 3-week dosing of pegloticase for refractory gout, including in organ transplant recipients. Arthritis Res Ther (2014) 1.06
Gout treatment and comorbidities: a retrospective cohort study in a large US managed care population. BMC Musculoskelet Disord (2011) 1.04
Epidemiology and management of gout in Taiwan: a nationwide population study. Arthritis Res Ther (2015) 0.98
Facilitators and barriers to adherence to urate-lowering therapy in African-Americans with gout: a qualitative study. Arthritis Res Ther (2014) 0.97
Understanding the dose-response relationship of allopurinol: predicting the optimal dosage. Br J Clin Pharmacol (2013) 0.95
Adherence to treatment guidelines in two primary care populations with gout. Rheumatol Int (2009) 0.94
Challenges faced by patients in gout treatment: a qualitative study. J Clin Rheumatol (2014) 0.91
[Full version of the S2e guidelines on gouty arthritis : Evidence-based guidelines of the German Society of Rheumatology (DGRh)]. Z Rheumatol (2016) 0.91
Gout. Novel therapies for treatment of gout and hyperuricemia. Arthritis Res Ther (2009) 0.90
The dynamics of chronic gout treatment: medication gaps and return to therapy. Am J Med (2010) 0.88
Modifiable factors associated with allopurinol adherence and outcomes among patients with gout in an integrated healthcare system. J Rheumatol (2014) 0.87
Veterans Affairs databases are accurate for gout-related health care utilization: a validation study. Arthritis Res Ther (2013) 0.85
Hyperuricemia and untreated gout are poor prognostic markers among those with a recent acute myocardial infarction. Arthritis Res Ther (2012) 0.83
The impact of gout on patient's lives: a study of African-American and Caucasian men and women with gout. Arthritis Res Ther (2014) 0.83
A qualitative and quantitative analysis of the characteristics of gout patient education resources. Clin Rheumatol (2013) 0.82
The efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age. BMC Geriatr (2012) 0.82
Adherence to uric acid treatment guidelines in a rheumatology clinic. Clin Rheumatol (2012) 0.81
New and improved strategies for the treatment of gout. Int J Nephrol Renovasc Dis (2010) 0.81
African American patients with gout: efficacy and safety of febuxostat vs allopurinol. BMC Musculoskelet Disord (2012) 0.81
Diabetes and gout: efficacy and safety of febuxostat and allopurinol. Diabetes Obes Metab (2013) 0.81
Lesinurad in combination with allopurinol: results of a phase 2, randomised, double-blind study in patients with gout with an inadequate response to allopurinol. Ann Rheum Dis (2016) 0.80
Prevention of comorbidity and acute attack of gout by uric acid lowering therapy. J Korean Med Sci (2014) 0.80
Adherence to the 2012 American College of Rheumatology (ACR) Guidelines for Management of Gout: A Survey of Brazilian Rheumatologists. PLoS One (2015) 0.79
Treatment approaches and adherence to urate-lowering therapy for patients with gout. Patient Prefer Adherence (2017) 0.78
Demographic and clinical features of gout patients in Turkey: a multicenter study. Rheumatol Int (2012) 0.78
The effects of febuxostat on the pharmacokinetic parameters of rosiglitazone, a CYP2C8 substrate. Br J Clin Pharmacol (2012) 0.78
Tophaceous gout and renal insufficiency: a new solution for an old therapeutic dilemma. Case Rep Med (2011) 0.78
Advances in gout: some answers, more questions. Arthritis Res Ther (2010) 0.78
An internet survey of common treatments used by patients with gout including cherry extract and juice and other dietary supplements. J Clin Rheumatol (2015) 0.77
Gout and the risk of dementia: a nationwide population-based cohort study. Arthritis Res Ther (2015) 0.77
Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study). Ann Rheum Dis (2016) 0.77
Can racial disparities in optimal gout treatment be reduced? Evidence from a randomized trial. BMC Med (2012) 0.76
Allopurinol reduces the risk of myocardial infarction (MI) in the elderly: a study of Medicare claims. Arthritis Res Ther (2016) 0.76
Allopurinol and the risk of stroke in older adults receiving medicare. BMC Neurol (2016) 0.76
Gout and risk of chronic kidney disease and nephrolithiasis: meta-analysis of observational studies. Arthritis Res Ther (2015) 0.76
A cross-sectional internet-based patient survey of the management strategies for gout. BMC Complement Altern Med (2016) 0.76
Factors associated with initiation and persistence of urate-lowering therapy. Arthritis Res Ther (2017) 0.75
Diagnosis and Treatment of Acute Gout at a University Hospital Emergency Department. Open Rheumatol J (2015) 0.75
Development of Therapeutic Chimeric Uricase by Exon Replacement/Restoration and Site-Directed Mutagenesis. Int J Mol Sci (2016) 0.75
Disease Control, Health Resource Use, Healthcare Costs, and Predictors in Gout Patients in the United States, the United Kingdom, Germany, and France: A Retrospective Analysis. Rheumatol Ther (2016) 0.75
Successful use of allopurinol in a patient on dialysis. BMJ Case Rep (2012) 0.75
Pegloticase for treatment of tophaceous polyarticular gout. Hawaii J Med Public Health (2013) 0.75
Critical appraisal of the role of pegloticase in the management of gout. Open Access Rheumatol (2012) 0.75
Frequency of hypertension in patients with gout. Mayo Clin Proc (2006) 0.75
The cost-effectiveness of HLA-b*5801 screening to guide initial urate-lowering therapy for gout in the United States. Semin Arthritis Rheum (2016) 0.75
A national survey of Veterans Affairs rheumatologists for relevance of quality of care indicators for gout management. Arthritis Care Res (Hoboken) (2010) 0.75
Utility of the Morisky Medication Adherence Scale in gout: a prospective study. Patient Prefer Adherence (2016) 0.75
Time Trends, Predictors, and Outcome of Emergency Department Use for Gout: A Nationwide US Study. J Rheumatol (2016) 0.75
Any link of gout disease control among hypertensive patients and onset of end-stage renal disease? Results from a population-based study. World J Nephrol (2017) 0.75
2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) (2012) 12.07
Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med (2006) 10.95
Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med (2005) 7.24
2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken) (2012) 5.22
Vitamin D intake is inversely associated with rheumatoid arthritis: results from the Iowa Women's Health Study. Arthritis Rheum (2004) 4.77
American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken) (2010) 4.65
2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res (Hoboken) (2011) 3.66
Initiation of tumor necrosis factor-α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA (2011) 3.58
Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice. Arthritis Care Res (Hoboken) (2012) 3.47
Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists. Arthritis Rheum (2007) 3.38
Serum uric acid and cardiovascular disease: recent developments, and where do they leave us? Am J Med (2005) 2.98
Gout and the risk of acute myocardial infarction. Arthritis Rheum (2006) 2.96
2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res (Hoboken) (2012) 2.83
The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar spine. J Bone Miner Res (2014) 2.52
Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. JAMA (2012) 2.51
Coffee, tea, and caffeine consumption and risk of rheumatoid arthritis: results from the Iowa Women's Health Study. Arthritis Rheum (2002) 2.43
Quality of life and disability in patients with treatment-failure gout. J Rheumatol (2009) 2.41
Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. Am J Med (2009) 2.27
Administrative codes combined with medical records based criteria accurately identified bacterial infections among rheumatoid arthritis patients. J Clin Epidemiol (2008) 2.25
Clinical value of monitoring BMD in patients treated with bisphosphonates for osteoporosis. J Bone Miner Res (2009) 2.24
Proton pump inhibitor utilization patterns in infants. J Pediatr Gastroenterol Nutr (2007) 2.17
Rates of malignancy associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum (2012) 2.15
Initiation of anti-TNF therapy and the risk of optic neuritis: from the safety assessment of biologic ThERapy (SABER) Study. Am J Ophthalmol (2012) 2.14
Benefits and harms of doxycycline treatment for Gulf War veterans' illnesses: a randomized, double-blind, placebo-controlled trial. Ann Intern Med (2004) 2.12
The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther (2010) 2.07
Risks of herpes zoster in patients with rheumatoid arthritis according to biologic disease-modifying therapy. Arthritis Care Res (Hoboken) (2015) 2.03
Re-using Mini-Sentinel data following rapid assessments of potential safety signals via modular analytic programs. Pharmacoepidemiol Drug Saf (2013) 2.01
Cigarette smoking and the risk of rheumatoid arthritis among postmenopausal women: results from the Iowa Women's Health Study. Am J Med (2002) 2.01
Obesity is not protective against fracture in postmenopausal women: GLOW. Am J Med (2011) 1.95
Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions. Ann Rheum Dis (2012) 1.95
Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. J Rheumatol (2009) 1.95
Trends in the use of biologic agents among rheumatoid arthritis patients enrolled in the US medicare program. Arthritis Care Res (Hoboken) (2013) 1.92
Hyperuricemia and incidence of hypertension among men without metabolic syndrome. Hypertension (2006) 1.90
Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years. J Clin Endocrinol Metab (2006) 1.88
Population-based assessment of adverse events associated with long-term glucocorticoid use. Arthritis Rheum (2006) 1.85
The effect of serum urate on gout flares and their associated costs: an administrative claims analysis. J Clin Rheumatol (2009) 1.82
Effect of co-morbidities on fracture risk: findings from the Global Longitudinal Study of Osteoporosis in Women (GLOW). Bone (2012) 1.79
A delphi exercise to identify characteristic features of gout - opinions from patients and physicians, the first stage in developing new classification criteria. J Rheumatol (2013) 1.77
Quality of care indicators for gout management. Arthritis Rheum (2004) 1.77
Measuring quality in arthritis care: methods for developing the Arthritis Foundation's quality indicator set. Arthritis Rheum (2004) 1.76
Randomized trial to improve fracture prevention in nursing home residents. Am J Med (2007) 1.75
Platelets can enhance vascular permeability. Blood (2012) 1.75
Serum urate levels and gout flares: analysis from managed care data. J Clin Rheumatol (2006) 1.70
Clinical diagnostic criteria for gout: comparison with the gold standard of synovial fluid crystal analysis. J Clin Rheumatol (2009) 1.70
Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout. Arthritis Rheum (2005) 1.70
Iyengar yoga for treating symptoms of osteoarthritis of the knees: a pilot study. J Altern Complement Med (2005) 1.69
Agreement and validity of pharmacy data versus self-report for use of osteoporosis medications among chronic glucocorticoid users. Pharmacoepidemiol Drug Saf (2006) 1.65
Impact of prevalent fractures on quality of life: baseline results from the global longitudinal study of osteoporosis in women. Mayo Clin Proc (2010) 1.62
Validity of gout diagnoses in administrative data. Arthritis Rheum (2007) 1.62
Risk factors for treatment failure with antiosteoporosis medication: the global longitudinal study of osteoporosis in women (GLOW). J Bone Miner Res (2014) 1.62
Longitudinal patterns in the prevention of osteoporosis in glucocorticoid-treated patients. Arthritis Rheum (2005) 1.58
The epidemiology of glucocorticoid-associated adverse events. Curr Opin Rheumatol (2008) 1.58
The management of gout at an academic healthcare center in Beijing: a physician survey. J Rheumatol (2006) 1.56
Longitudinal trends in use of bone mass measurement among older americans, 1999-2005. J Bone Miner Res (2008) 1.55
Rilonacept (interleukin-1 trap) for prevention of gout flares during initiation of uric acid-lowering therapy: results from a phase III randomized, double-blind, placebo-controlled, confirmatory efficacy study. Arthritis Care Res (Hoboken) (2012) 1.53
Derivation and preliminary validation of an administrative claims-based algorithm for the effectiveness of medications for rheumatoid arthritis. Arthritis Res Ther (2011) 1.53
Correlation of T1rho with fixed charge density in cartilage. J Magn Reson Imaging (2004) 1.49
OMERACT 6 brings new perspectives to rheumatology measurement research. J Rheumatol (2003) 1.47
Benefit of adherence with bisphosphonates depends on age and fracture type: results from an analysis of 101,038 new bisphosphonate users. J Bone Miner Res (2008) 1.47
Blood transfusion, alcohol use, and anthropometric risk factors for rheumatoid arthritis in older women. J Rheumatol (2002) 1.46
Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster. JAMA (2013) 1.45
Identification and validation of vertebral compression fractures using administrative claims data. Med Care (2009) 1.45
Recent trends in hip fracture rates by race/ethnicity among older US adults. J Bone Miner Res (2012) 1.44
Early arthritis clinics. Much early arthritis is unclassified. J Rheumatol (2002) 1.43
Optimizing CAD diagnosis in China with CT angiography. J Cardiovasc Comput Tomogr (2009) 1.43
Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum (2012) 1.43
The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agents. Ann Rheum Dis (2011) 1.42
Disease-related and all-cause health care costs of elderly patients with gout. J Manag Care Pharm (2008) 1.42
Empirically based composite fracture prediction model from the Global Longitudinal Study of Osteoporosis in Postmenopausal Women (GLOW). J Clin Endocrinol Metab (2014) 1.41
Challenges in improving the quality of osteoporosis care for long-term glucocorticoid users: a prospective randomized trial. Arch Intern Med (2007) 1.41
Population-based fracture risk assessment and osteoporosis treatment disparities by race and gender. J Gen Intern Med (2009) 1.40
Cost of gestational diabetes mellitus in the United States in 2007. Popul Health Manag (2009) 1.38
Antioxidant micronutrients and risk of rheumatoid arthritis in a cohort of older women. Am J Epidemiol (2003) 1.35
Improving the prediction of medication compliance: the example of bisphosphonates for osteoporosis. Med Care (2009) 1.31
Low-dose prednisone chronotherapy for rheumatoid arthritis: a randomised clinical trial (CAPRA-2). Ann Rheum Dis (2012) 1.31
Study design for a comprehensive assessment of biologic safety using multiple healthcare data systems. Pharmacoepidemiol Drug Saf (2011) 1.30
Previous fractures at multiple sites increase the risk for subsequent fractures: the Global Longitudinal Study of Osteoporosis in Women. J Bone Miner Res (2012) 1.29
Injectable corticosteroids in modern practice. J Am Acad Orthop Surg (2005) 1.28
Central DXA utilization shifts from office-based to hospital-based settings among medicare beneficiaries in the wake of reimbursement changes. J Bone Miner Res (2012) 1.27
Detection of changes in articular cartilage proteoglycan by T(1rho) magnetic resonance imaging. J Orthop Res (2005) 1.27
Differential expression of three Chlamydia trachomatis hsp60-encoding genes in active vs. persistent infections. Microb Pathog (2004) 1.27
Poor validation of medical record ICD-9 diagnoses of gout in a veterans affairs database. J Rheumatol (2009) 1.27
Drug-specific and time-dependent risks of bacterial infection among patients with rheumatoid arthritis who were exposed to tumor necrosis factor alpha antagonists. Arthritis Rheum (2007) 1.26
Medical cost associated with prediabetes. Popul Health Manag (2009) 1.22
Predicting fractures in an international cohort using risk factor algorithms without BMD. J Bone Miner Res (2011) 1.22
Treatment of rheumatoid arthritis. Am J Health Syst Pharm (2006) 1.21
The economic burden of gout on an employed population. Curr Med Res Opin (2006) 1.20
Health services utilization after fractures: evidence from Medicare. J Gerontol A Biol Sci Med Sci (2010) 1.19
Relationship of weight, height, and body mass index with fracture risk at different sites in postmenopausal women: the Global Longitudinal study of Osteoporosis in Women (GLOW). J Bone Miner Res (2014) 1.19
Chlamydia trachomatis genes whose products are related to energy metabolism are expressed differentially in active vs. persistent infection. Microbes Infect (2002) 1.19
Health care expenditures associated with skeletal fractures among Medicare beneficiaries, 1999-2005. J Bone Miner Res (2009) 1.18
New classification criteria for gout: a framework for progress. Rheumatology (Oxford) (2013) 1.16
Sodium magnetic resonance imaging of proteoglycan depletion in an in vivo model of osteoarthritis. Acad Radiol (2004) 1.14
Racial disparities in the receipt of osteoporosis related healthcare among community-dwelling older women with arthritis and previous fracture. J Rheumatol (2005) 1.12
Quality indicators for the care of osteoarthritis in vulnerable elders. J Am Geriatr Soc (2007) 1.12
Gout-related health care utilization in US emergency departments, 2006 through 2008. Arthritis Care Res (Hoboken) (2013) 1.10